ATE339453T1 - Spezifische antikörper für cyp1b1 - Google Patents

Spezifische antikörper für cyp1b1

Info

Publication number
ATE339453T1
ATE339453T1 AT00911087T AT00911087T ATE339453T1 AT E339453 T1 ATE339453 T1 AT E339453T1 AT 00911087 T AT00911087 T AT 00911087T AT 00911087 T AT00911087 T AT 00911087T AT E339453 T1 ATE339453 T1 AT E339453T1
Authority
AT
Austria
Prior art keywords
cyp1b1
cancer
antibodies
specific antibodies
bind
Prior art date
Application number
AT00911087T
Other languages
English (en)
Inventor
William Melvin
Graeme Ian Murray
Original Assignee
Univ Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aberdeen filed Critical Univ Aberdeen
Application granted granted Critical
Publication of ATE339453T1 publication Critical patent/ATE339453T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00911087T 1999-03-19 2000-03-20 Spezifische antikörper für cyp1b1 ATE339453T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9906380.2A GB9906380D0 (en) 1999-03-19 1999-03-19 Monoclonal antibodies specific for cypibi

Publications (1)

Publication Number Publication Date
ATE339453T1 true ATE339453T1 (de) 2006-10-15

Family

ID=10849980

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00911087T ATE339453T1 (de) 1999-03-19 2000-03-20 Spezifische antikörper für cyp1b1

Country Status (10)

Country Link
US (2) US7419794B1 (de)
EP (1) EP1163272B1 (de)
JP (2) JP2002543765A (de)
AT (1) ATE339453T1 (de)
AU (1) AU768885B2 (de)
CA (1) CA2365121A1 (de)
DE (1) DE60030696T2 (de)
ES (1) ES2272261T3 (de)
GB (1) GB9906380D0 (de)
WO (1) WO2000056773A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035810A2 (en) * 1999-11-15 2001-05-25 Dana-Farber Cancer Institute, Inc. Cancer immunotherapy and diagnosis using cytochrome p450 1b1
GB0002835D0 (en) * 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
US7241742B2 (en) 2000-10-31 2007-07-10 Mgi Pharma Biologics, Inc. CYP1B1 nucleic acids and methods of use
US7385023B1 (en) 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
GB0803071D0 (en) 2008-02-20 2008-03-26 Care Technologies Inc Cancer detection methods and techniques
WO2012075136A2 (en) * 2010-11-30 2012-06-07 Fox Chase Cancer Center Targeting of cyp1b1 in the treatment of head and neck cancer and lung cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938948A (en) * 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5688773A (en) * 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
GB9519490D0 (en) * 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use

Also Published As

Publication number Publication date
US20090023160A1 (en) 2009-01-22
EP1163272B1 (de) 2006-09-13
EP1163272A1 (de) 2001-12-19
AU3308100A (en) 2000-10-09
GB9906380D0 (en) 1999-05-12
JP2011157363A (ja) 2011-08-18
AU768885B2 (en) 2004-01-08
WO2000056773A1 (en) 2000-09-28
DE60030696T2 (de) 2007-10-04
CA2365121A1 (en) 2000-09-28
JP2002543765A (ja) 2002-12-24
DE60030696D1 (de) 2006-10-26
US7419794B1 (en) 2008-09-02
ES2272261T3 (es) 2007-05-01

Similar Documents

Publication Publication Date Title
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
ATE516047T1 (de) Ovr110-antikörperzusammensetzungen und anwendungsverfahren
NO20026245L (no) Forbedring av antistoff-cytokinfusjonsproteinformidlede immunresponser vedkombinert behandling med immuncytokinopptakforbedrende midler
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
WO2003048328A3 (en) Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
WO2005046573A3 (en) Pro104 antibody compositions and methods of use
EP1893196A4 (de) Diarylhydantoin-verbindungen
EP1383785A4 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
WO2006099141A3 (en) Anti-mesothelin antibodies
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
WO2010060186A8 (en) Antibodies that specifically block the biological activity of a tumor antigen
MX2023014069A (es) Composiciones y métodos para el tratamiento del cáncer de próstata.
SI1572087T1 (sl) Protitelesa proti antigenu tmeff2 raka in njihovauporaba
DE69939819D1 (de) Verfahren zur krebsdiagnose mittels eines chimärischen toxin
WO2021263227A3 (en) Anti-nme antibody and method of treating cancer or cancer metastasis
WO2021252551A3 (en) Anti-nme antibody and method of treating cancer or cancer metastasis
ATE339453T1 (de) Spezifische antikörper für cyp1b1
ATE425460T1 (de) Antikörper, immunoassay und verfahren zum nachweis von prostatakrebs
MX2025000819A (es) Metodos para el tratamiento de pacientes con cancer urotelial localmente avanzado o metastasico con conjugados de anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12 en combinacion con pembrolizumab
WO2022033978A3 (en) Cancer treatment methods using anti-cd73 antibodies
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
MX2023010825A (es) Metodos para tratar el cancer con anticuerpos anti-ilt3.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties